pulmonary sarcomatoid carcinoma
Recently Published Documents


TOTAL DOCUMENTS

161
(FIVE YEARS 93)

H-INDEX

11
(FIVE YEARS 4)

2021 ◽  
Author(s):  
Li Xu ◽  
Ning‐ning Tao ◽  
Bin Liang ◽  
Dao‐wei Li ◽  
Huai‐chen Li ◽  
...  

2021 ◽  
Author(s):  
Yue Zheng ◽  
Yang Fu ◽  
Qin Zhong ◽  
Rong Deng ◽  
Yu Zhang

Pulmonary sarcomatoid carcinoma (PSC) is a pathological subtype of non-small cell lung cancer. Although the incidence of PSC in lung cancer is very low, it is an aggressive cancer, leading to a poor prognosis. Currently, there is no standard treatment for advanced PSC. Targeted therapy can be used for patients with MET exon 14 mutations and patients with other driver gene mutations may also benefit from treatment. The emergence of immune checkpoint inhibitors also provides potential options for advanced PSC treatment, but more clinical data is needed. Additionally, more research may be warranted to explore the effects of chemotherapy, radiotherapy and antiangiogenic therapy. In this review, the authors summarize the research regarding the treatment of advanced PSC.


2021 ◽  
Author(s):  
Shuyue Jiao ◽  
Xiao Zhang ◽  
Ruilin Wang ◽  
Hui Zhu ◽  
Shaomei Li ◽  
...  

Abstract Pulmonary sarcomatoid carcinoma (PSC) is a highly aggressive rare subtype of non-small cell lung cancer (NSCLC). PSC is known for its poor prognosis and low sensitivity to conventional treatments such as chemotherapy, radiation, and adjuvant therapies. In recent years, the application of targeted therapy and immunotherapy in this field has made progress. Although programmed cell death 1 (PD-1) inhibitors have been reported to show favorable antitumor effects in PSC patients with high programmed death-ligand 1 (PD-L1) expression, the efficacy of PD-1 inhibitors in combination with antiangiogenic drugs has not been investigated. Here, we report for the first time a case of dual-source cancer with low expression of PD-L1 and microsatellite stability (MSS) which showed continuous response to sintilimab combined with anlotinib as first-line treatment and achieved a long progression free survival (PFS) of 24 months with no serious adverse reactions. This case presents a new therapeutic prospect for PSC and a potential to enhance its prognosis and treatment strategies.


Medicine ◽  
2021 ◽  
Vol 100 (45) ◽  
pp. e27813
Author(s):  
Le Wang ◽  
Jing Zhang ◽  
Xing Chen ◽  
Maoli Liang ◽  
Shuo Li ◽  
...  

2021 ◽  
pp. 1-10
Author(s):  
Ferhat Ferhatoglu ◽  
Fahmin Amirov ◽  
Berker Ozkan ◽  
Murat Kara ◽  
Alper Toker ◽  
...  

<b><i>Introduction:</i></b> Pulmonary sarcomatoid carcinoma (PSC) is a very rare subtype of non-small-cell lung cancer (NSCLC). It is frequently diagnosed in the advanced stage and is resistant to conventional chemotherapeutics. Due to the unique nature and rarity, we evaluated the epidemiological, clinicopathological, and survival data of PSC patients treated at our centre. <b><i>Patients and Methods:</i></b> We retrospectively collected demographic and clinical data of 67 PSC patients from a single tertiary referral hospital, between the 2000 and 2018. Univariate and multivariate analyses were performed to determine the risk factors affecting survival. <b><i>Results:</i></b> The median age was 61 years, and the percentage of male was 74.6%. Most of the patients had a smoking history (76.9%). The most common PSC subtype was pleomorphic carcinoma (46.3%). The median overall survival (OS) was 55.4 months, and the 5-year OS rate was 47.5%. Advanced stage, T4 tumour, and positive lymph node involvement were associated with poor OS (<i>p</i> &#x3c; 0.05). The patients with negative epithelial markers had poorer prognosis (<i>p</i> = 0.027) and had more frequently stage IV disease (<i>p</i> = 0.016). Surgical treatment and stage IV disease were determined to be independent prognostic factors. <b><i>Conclusion:</i></b> PSC is an extremely rare and aggressive variant of NSCLC. Positive epithelial markers may have favourable prognostic significance in PSC. Resection of the tumour with a negative surgical margin is crucial for better survival. The prognosis of the disease is very poor in the metastatic stage.


Sign in / Sign up

Export Citation Format

Share Document